ArticleEuropean journal of nuclear medicine and molecular imaging2015
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Article in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.Molecular imaging and biology · 2020Pooled it
- Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.European journal of nuclear medicine and molecular imaging · 2018Trial
- Prospective evaluation of [European journal of nuclear medicine and molecular imaging · 2016Trial
- Correlation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Flare phenomenon visualized byAnnals of nuclear medicine · 2024Article
- PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?Journal of clinical medicine · 2023Review
- Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2023Observational
- Current status of PSMA-targeted imaging and therapy.Frontiers in oncology · 2023Review
- The Role of [Biomedicines · 2022Article
- Review
- Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.Molecular oncology · 2022Article
- Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Response Assessment and Prediction of Progression-Free Survival byBiomolecules · 2021Article
- Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging.Therapeutic advances in medical oncology · 2021Review
- Exploratory study ofAmerican journal of nuclear medicine and molecular imaging · 2021Article
- Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology.Medicina (Kaunas, Lithuania) · 2020Review
- Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer.International urology and nephrology · 2019Article
- Treatment Response Assessment of Skeletal Metastases in Prostate Cancer withNuclear medicine and molecular imaging · 2019Article
- Article
- Prognostic Value ofContrast media & molecular imaging · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe investigated the role of (18)F-methylcholine (FCH) PET/CT in the early evaluation of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.
methodsThe study group comprised 36 patients with a median age of 72 years (range 48-90 years) who were treated with enzalutamide 160 mg once daily after at least one chemotherapeutic regimen with docetaxel. Patients were evaluated monthly for serological prostate-specific antigen (PSA) response. FCH PET/CT was performed at baseline and repeated after 3-6 weeks. Univariate and multivariate Cox regression models addressed potential predictors of progression-free survival (PFS) and overall survival (OS).
resultsAt a median follow-up of 24.2 months (range 1.8-27.3 months), 34 patients were evaluable for early FCH PET/CT evaluation of response, and of these 17 showed progressive disease (PD) and 17 had stable disease or a partial response. A decrease in PSA level of more than 50% was observed in 21 patients. Early FCH PET/CT PD predicted radiological PD 3 months in advance of CT in 12 of 18 patients (66%) and was discordant with the decrease in PSA level in 13 patients. In 6 of these, biochemical PD was confirmed in 2 months. In multivariate analysis, only decrease in PSA level and FCH PET/CT were significant predictors of PFS (p = 0.0005 and p = 0.029, respectively), whereas decrease in PSA level alone was predictive of OS (p = 0.007).
conclusionThis is one of the first studies to evaluate the role of FCH PET/CT as an early predictor of outcome in mCRPC patients treated with enzalutamide. Our preliminary results suggest that the combination of FCH PET/CT and decrease in PSA level could be a valid tool to predict PFS in mCRPC patients. PSA remains the single most important prognostic factor, while FCH PET/CT does not add more information on OS beyond that obtained from PSA. Further studies in larger populations are needed to confirm these data and to clarify the role of FCH PET/CT in predicting response to enzalutamide in mCRPC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.